Tag: ESC 2018
ESC 2018: TMVI associated with “excellent outcomes” for valve-in-valve procedures
New results from the TMVR (Transcatheter mitral valve replacement) Registry show that patients w...
ESC 2018: More evidence that FFRCT is an effective approach for identifying patients who do not require further intervention
Bjarne L Nørgaard (Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark) and co...
ESC 2018: First US FDA-approved study shows TAVI is safe for low-risk patients
The LRT (Low Risk TAVR) trial did not find any significant differences in the rate of all-cause ...
ESC 2018: Novel imaging biomarker can predict risk of cardiac mortality
Milind Desai (Cleveland Clinic, Cleveland, USA) and colleagues have identified a novel imaging bioma...
ESC 2018: All-cause mortality in cardiogenic shock multivessel PCI only increased during first 30 days
One-year data from the CULPRIT-SHOCK trial indicate that there is no significant difference in all-c...
ESC 2018: Ticagrelor monotherapy approach does not challenge current DAPT approach
The GLOBAL LEADERS trial, simultaneously published in the Lancet and presented at the 2018 Europ...
ESC 2018: No difference in MACE between drug-coated balloons and drug-eluting stents for de novo lesions in small vessels
The 12-months results of the BASKET-SMALL 2 study, which were presented at the 2018 European Society...
ESC 2018: Higher all-cause mortality with Orsiro at five years than with Xience
According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biod...
ESC 2018: MitraClip makes “absolutely no difference” for the prognosis of secondary mitral valve regurgitation
The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Ab...
ESC 2018: Greater use of PCI for high SYNTAX score patients may explain higher rate of all-cause death with FFR in FUTURE
The final results of the FUTURE (Functional testing underlying revascularisation) trial indicate...
ESC 2018: DAPT score “not generalisable” to a nationwide population
A new study has found that the dual antiplatelet therapy (DAPT) score, which is recommended by b...
ESC 2018: Non-atherosclerotic spontaneous coronary artery dissection predominantly affects young to middle-aged women
Data from the Canadian Spontaneous Coronary Artery Disease (CanSCAD) study indicate that the maj...
ESC 2018: Cardioskin launched
WeHealth, by Servier, has launched Cardioskin—a connected solution that is designed to function as a...
Twenty thousand patients have now been treated with RenalGuard therapy
RenalGuard Solutions has announced the treatment of 20,000 patients with RenalGuard for the prev...
ESC 2018: Society calls for abstract submissions for its next congress
The European Society of Cardiology (ESC) has released a new video, see below, that outlines the reas...
